CD Bioparticles Announces Carbon-based Nanocages Production Services for Researchers

As a leading manufacturer and supplier of various drug delivery products and services, CD Bioparticles now introduces carbon-based nanocages production services to global researchers for R&D and commercialization in a variety of application areas. Custom services for designing and synthesizing carbon-based nanomaterials with special required drugs loading, together with its analysis and characterization before and after drug encapsulation are available at CD Bioparticles now.

Carbon-based nanocages, namely fullerene, carbon nanotubes (a one-atom-thick sheet of graphite rolled into a tube with a diameter of one nanometer), and graphene (a single atomic layer of sp2 hybridized carbon atoms), have attracted significant attention since their discoveries, and they have been playing a significant role in nanoscience and nanotechnology these days. CD Bioparticles now offers well-designed carbon-based nanocages as fullerene, carbon nanotubes, and graphene and its derivatives. Researchers may select the material type, particle size, size distribution, and surface functional groups such as carboxyl at CD Bioparticles.

“CD Bioparticles is specialized in the development of drug delivery systems and customizing nanoparticles for drug delivery utilizing its core technologies. We have strong and broad expertise and years of experience in the drug delivery field, and our team will work closely with you to accelerate your research development progress. In combination with our technologies, high-quality products and services, the efficacy of your drug delivery can be tremendously improved.” said Dr. Jessica Waldorf, chief scientific officer of R&D department of CD Bioparticles.

“CD Bioparticles is committed to supporting its clients to find the drug delivery solution that best fits their needs. We collaborate with the academia and industry to support their drug discovery and development process, and we have a team of experienced experts who know how to help our customers through all stages of the development process, from formulation development to preclinical trials. This new carbon-based nanocages production service for nanotechnology applications will enable researchers to achieve deeper insights and advance their understanding, which will ultimately lead to crucial breakthroughs in the scientific research. We’ll also continue to focus on providing outstanding support to our clients for customized solutions by developing new and biocompatible drug delivery systems.” said Prof. Jeffrey A. Depaul, M.D., the chief scientific officer of R&D department of CD Bioparticles.

For more detailed information on carbon-based nanocages production services or to discover more, please contact CD Bioparticles directly at 1-631-619-7922.

About CD Bioparticles
CD Bioparticles is an established drug delivery company which provides customized solutions for developing and producing new, biocompatible drug delivery systems. It specializes in a range of formulation and drug delivery technologies, from conventional liposomes, PEGylated liposomes for drug delivery to polymer microspheres and nanoparticles for enhanced drug delivery. It provides contract services of drug delivery formulation developments for basic research, formulation feasibility studies, process development and scale-up, formulation characterization, analytical and nonclinical services.